Rice Hall James & Associates’s TherapeuticsMD TXMD Stock Holding History

Rice Hall James & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,354	Closed	-$443K	–	272
2020 Q1	$443K	Sell	8,354 -2,489	-23%	-$247K	0.02%	244
2019 Q4	$1.31M	Sell	10,843 -709	-6%	-$102K	0.04%	218
2019 Q3	$2.1M	Buy	11,552 +338	+3%	+$47.6K	0.08%	163
2019 Q2	$1.46M	Buy	11,214 +577	+5%	+$103K	0.05%	218
2019 Q1	$2.59M	Buy	10,637 +8,580	+417%	+$2.27M	0.08%	158
2018 Q4	$392K	Buy	+2,057	New	+$502K	0.01%	271

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rice Hall James & Associates's TXMD Position: Q2 2020 in Review

Rice Hall James & Associates sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 8,354 shares — an estimated $443K sold.

Rice Hall James & Associates first reported a position in TXMD in Q4 2018 and held it in 6 quarters. The position peaked at $2.59M in Q1 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

Rice Hall James & Associates reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
Rice Hall James & Associates sold 8,354 TherapeuticsMD shares in Q2 2020, an estimated $443K.
Rice Hall James & Associates first reported a position in TherapeuticsMD in Q4 2018 and held it in 6 quarters.
Rice Hall James & Associates's TherapeuticsMD position peaked at $2.59M in Q1 2019.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Rice Hall James & Associates's 13F filing for Q2 2020, filed 14 Aug 2020.